Predictors for development of palbociclib-induced neutropenia in breast cancer patients as determined by ordered logistic regression analysis

Abstract This retrospective study aimed to identify predictors for the development of palbociclib-induced neutropenia. This study retrospectively analysed 78 breast cancer patients who had received palbociclib at our hospital between January 2018 and May 2020. For the regression analysis of factors...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Yuko Kanbayashi, Koichi Sakaguchi, Takeshi Ishikawa, Koichi Takayama, Tetsuya Taguchi
Format:	article
Langue:	EN
Publié:	Nature Portfolio 2021
Sujets:	Medicine R Science Q
Accès en ligne:	https://doaj.org/article/7e65446849354672bb53b9a0f067b4e2
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

id	oai:doaj.org-article:7e65446849354672bb53b9a0f067b4e2
record_format	dspace
spelling	oai:doaj.org-article:7e65446849354672bb53b9a0f067b4e22021-12-02T16:56:43ZPredictors for development of palbociclib-induced neutropenia in breast cancer patients as determined by ordered logistic regression analysis10.1038/s41598-021-99504-52045-2322https://doaj.org/article/7e65446849354672bb53b9a0f067b4e22021-10-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-99504-5https://doaj.org/toc/2045-2322Abstract This retrospective study aimed to identify predictors for the development of palbociclib-induced neutropenia. This study retrospectively analysed 78 breast cancer patients who had received palbociclib at our hospital between January 2018 and May 2020. For the regression analysis of factors associated with palbociclib-induced neutropenia, variables were extracted manually from medical charts. The level of palbociclib-induced neutropenia was evaluated using the National Cancer Institute’s Common Terminology Criteria for Adverse Events (version 5). Multivariate ordered logistic regression analysis was performed to identify predictors for the development of neutropenia. Optimal cut-off thresholds were determined using receiver operating characteristic (ROC) analysis. Values of P < 0.05 (2-tailed) were considered significant. Significant factors identified included concomitant use of statin (odds ratio [OR] = 0.104, 95% confidence interval [CI] = 0.018–0.598; P = 0.011) and body mass index (BMI) (OR = 1.118, 95% CI = 1.007–1.241; P = 0.037). ROC analysis revealed that neutropenia (grade 4) was more likely to occur with a BMI ≥ 22.3 kg/m2. In conclusion, no concomitant use of statins and high BMI were identified as significant predictors for the development of palbociclib-induced neutropenia.Yuko KanbayashiKoichi SakaguchiTakeshi IshikawaKoichi TakayamaTetsuya TaguchiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-5 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yuko Kanbayashi Koichi Sakaguchi Takeshi Ishikawa Koichi Takayama Tetsuya Taguchi Predictors for development of palbociclib-induced neutropenia in breast cancer patients as determined by ordered logistic regression analysis
description	Abstract This retrospective study aimed to identify predictors for the development of palbociclib-induced neutropenia. This study retrospectively analysed 78 breast cancer patients who had received palbociclib at our hospital between January 2018 and May 2020. For the regression analysis of factors associated with palbociclib-induced neutropenia, variables were extracted manually from medical charts. The level of palbociclib-induced neutropenia was evaluated using the National Cancer Institute’s Common Terminology Criteria for Adverse Events (version 5). Multivariate ordered logistic regression analysis was performed to identify predictors for the development of neutropenia. Optimal cut-off thresholds were determined using receiver operating characteristic (ROC) analysis. Values of P < 0.05 (2-tailed) were considered significant. Significant factors identified included concomitant use of statin (odds ratio [OR] = 0.104, 95% confidence interval [CI] = 0.018–0.598; P = 0.011) and body mass index (BMI) (OR = 1.118, 95% CI = 1.007–1.241; P = 0.037). ROC analysis revealed that neutropenia (grade 4) was more likely to occur with a BMI ≥ 22.3 kg/m2. In conclusion, no concomitant use of statins and high BMI were identified as significant predictors for the development of palbociclib-induced neutropenia.
format	article
author	Yuko Kanbayashi Koichi Sakaguchi Takeshi Ishikawa Koichi Takayama Tetsuya Taguchi
author_facet	Yuko Kanbayashi Koichi Sakaguchi Takeshi Ishikawa Koichi Takayama Tetsuya Taguchi
author_sort	Yuko Kanbayashi
title	Predictors for development of palbociclib-induced neutropenia in breast cancer patients as determined by ordered logistic regression analysis
title_short	Predictors for development of palbociclib-induced neutropenia in breast cancer patients as determined by ordered logistic regression analysis
title_full	Predictors for development of palbociclib-induced neutropenia in breast cancer patients as determined by ordered logistic regression analysis
title_fullStr	Predictors for development of palbociclib-induced neutropenia in breast cancer patients as determined by ordered logistic regression analysis
title_full_unstemmed	Predictors for development of palbociclib-induced neutropenia in breast cancer patients as determined by ordered logistic regression analysis
title_sort	predictors for development of palbociclib-induced neutropenia in breast cancer patients as determined by ordered logistic regression analysis
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/7e65446849354672bb53b9a0f067b4e2
work_keys_str_mv	AT yukokanbayashi predictorsfordevelopmentofpalbociclibinducedneutropeniainbreastcancerpatientsasdeterminedbyorderedlogisticregressionanalysis AT koichisakaguchi predictorsfordevelopmentofpalbociclibinducedneutropeniainbreastcancerpatientsasdeterminedbyorderedlogisticregressionanalysis AT takeshiishikawa predictorsfordevelopmentofpalbociclibinducedneutropeniainbreastcancerpatientsasdeterminedbyorderedlogisticregressionanalysis AT koichitakayama predictorsfordevelopmentofpalbociclibinducedneutropeniainbreastcancerpatientsasdeterminedbyorderedlogisticregressionanalysis AT tetsuyataguchi predictorsfordevelopmentofpalbociclibinducedneutropeniainbreastcancerpatientsasdeterminedbyorderedlogisticregressionanalysis
_version_	1718382748588048384

Predictors for development of palbociclib-induced neutropenia in breast cancer patients as determined by ordered logistic regression analysis

Documents similaires